IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
IDEAYA Biosciences announced that the Phase 2/3 OptimUM-02 trial data for darovasertib in combination with crizotinib has been selected for a late-breaking abstract oral presentation at the 2026 ASCO Annual Meeting. The presentation will provide complete data details that were not included in the company's prior topline release regarding the first-line treatment of HLA*A2-negative metastatic uveal melanoma. Dr.
Key figures
- Drug Name
- darovasertib
- Phase Of Trial
- Phase 2/3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.